The Regulatory Affairs (RA) department is a key discipline in the global network of drug development. During drug development, regulatory strategy is one crucial success factor for the approval of the development candidate. Also, regulatory strategy can optimise labelling in the key countries in order to maximise the market success. No submission and approval would be possible without the appropriate dossier composition and compilation. Without adherence to the respective guidance documents and scientific advice from Health Authorities to design the optimal clinical development plan, optimal labelling would not be feasible. These two examples show some characteristics of the regulatory strategy: it is highly interactive with other disciplines and it is heavily based on a thorough intelligence work which enables the RA Manager to know the “rules of the game” and to develop the optimal regulatory strategy for the current development candidate. The major cornerstone for developing a regulatory strategy is regulatory intelligence.
This document focuses on regulatory intelligence. The regulatory contributions to the global drug development from early research to submission are described. Strategies for generic drugs as well as detailed strategies for life-cycle management are excluded.
Major components of regulatory intelligence are:
• Competitor Information
• Information on Regulatory Environment
• Information on Legal Requirements
Competitor analysis is an essential aspect of the intelligence work. Sources of competitive information as well as relevant items of competitive information are described.
Sources of information about the regulatory environment and sources of information about the legal regulatory environment are described and their tremendous impact on setting up and modifying the regulatory strategy evaluated.
Special attention is paid to the components and sources of regulatory intelligence information (e.g. Internet links and documents related to intelligence information). Some examples show how regulatory intelligence information supports the regulatory strategic considerations.
The last section describes the regulatory strategy itself and examples of how regulatory intelligence acts as the basis for setting up the regulatory strategy. What is the basis of strategic considerations, what are the considerations, what are the major components of a regulatory strategy, how do the different disciplines involved in drug development work together?
Table of Contents
2. INTRODUCTION
3. COMPONENTS OF REGULATORY INTELLIGENCE
3.1 COMPETITOR INFORMATION
3.1.1 Criteria for the definition of relevant competitors
3.1.2 Essential information to be gathered about competitors
3.1.2.1 Trade name
3.1.2.2 International Non-proprietary Name (INN)
3.1.2.3 Drug class
3.1.2.4 Type of Procedure
3.1.2.5 Countries and the associated Submission date / Approval date
3.1.2.6 Clinical trials presented in the dossier
3.1.2.7 Competitor labelling
3.1.3 Sources of Competitor Information
3.1.3.1 Authority Homepages
3.1.3.2 Company Homepages
3.1.3.3 Scientific Publications
3.1.3.4 Scientific Internet Search Engines
3.1.3.5 General Internet Search Engines
3.1.3.6 Labelling Databases
3.2 REGULATORY ENVIRONMENT
3.2.1 Agency Benchmarks
3.2.1.1 FDA
3.2.1.2 EMEA
3.2.1.3 Germany
3.2.1.4 France
3.2.1.5 Conclusion
3.2.2 Regulatory Precedents on Other Products
3.2.3 Ongoing and Future Regulatory Changes
3.2.3.1 Review 2001 (Europe)
3.2.3.2 EU Enlargement
3.2.3.3 Implementation of the Clinical Trial directive (Directive 2001/20/EC)
3.2.3.4 Implementation of the CTD structure for Dossiers
3.2.4 Trade Associations
3.2.4.1 VFA
3.2.4.2 EFPIA
3.2.4.3 JPMA
3.2.4.4 PhRMA
3.2.4.5 IFPMA
3.2.5 Regulatory Associations
3.2.6 WHO
3.2.7 Training courses and Meetings
3.3 LEGAL REQUIREMENTS
3.3.1 General Requirements
3.3.1.1 Supra-national Guidance - Example: ICH
3.3.1.2 Europe
3.3.1.3 Japan
3.3.1.4 USA
3.3.1 Therapeutic Area Guidance – Example: Microbial Diseases
3.3.2 Special Populations – Example: Paediatric Patients
3.3.3 Orphan Drug Designation
4. REGULATORY STRATEGY
4.1 DEFINITION OF “GLOBAL REGULATORY STRATEGY”
4.2 REGULATORY AFFAIRS STRATEGIC CONTRIBUTIONS TO THE GLOBAL MULTIDISCIPLINARY DEVELOPMENT PLAN
4.2.1 Competitor Analysis and Target Labelling
4.2.2 Definition of Trade Name and INN
4.2.3 Definition of Key Markets
4.2.4 Definition of a Clinical Development Plan
4.2.5 Identification and Validation of Relevant Guidelines
4.2.6 Life Cycle Management Strategy
4.3 REGULATORY STRATEGY AND IMPACT ON OTHER DISCIPLINES
4.3.1 Submission Strategy
4.3.2 Strategy for Meetings with Health Authorities
4.3.3 Issue Management
5. DISCUSSION
Objectives and Key Themes
This work examines the pivotal role of regulatory intelligence as a fundamental prerequisite for developing effective regulatory strategies throughout the drug development lifecycle until submission. The central research focus is to demonstrate how systematic intelligence gathering—concerning competitors, regulatory environments, and legal requirements—enables regulatory affairs managers to optimize drug development plans and navigate the complex "rules of the game" to maximize return on investment.
- Strategic integration of competitor analysis and target labelling in drug development.
- Navigation of complex international regulatory environments and agency benchmarks.
- Impact of legal requirements and evolving guidance on global drug development.
- Management of interactions with health authorities, including scientific advice and meetings.
- Strategic handling of specialized development areas like orphan drugs and paediatric populations.
Excerpt from the Book
3.1.2.1 Trade name
Trade names can be different in different regions and countries. The assignment of a trade name depends on cultural and linguistic habits. In addition to this, trade names need to be distinguishable from similar trade names in the country in order to avoid confusion in the pharmacies. Therefore, it is essential to have an overview on existing trade names in the target region / country. If a company aims for one global trade name this name needs to be acceptable to all target countries with their national languages. If the name sounds acceptable for English speaking countries it may have an unacceptable meaning in other languages. An example is the Mitsubishi car “Pajero” which is acceptable in English but means a strong insult in Spanish. So, the overview on already existing trade names is a basis to think about potential own trade names.
Chapter Summaries
2. INTRODUCTION: Explains regulatory intelligence as a necessary prerequisite for drug development strategy, excluding post-approval life cycle management and generic drugs.
3. COMPONENTS OF REGULATORY INTELLIGENCE: Details the primary pillars of intelligence gathering, specifically competitor information, analysis of the regulatory environment, and understanding legal requirements.
4. REGULATORY STRATEGY: Defines the concept of global regulatory strategy and outlines how regulatory affairs strategically contributes to multidisciplinary development plans, including submission tactics and issue management.
5. DISCUSSION: Evaluates the shift of regulatory affairs from a cost-intensive "post office" function to a key strategic discipline that directly influences the success of drug development and company financial outcomes.
Keywords
Regulatory Intelligence, Regulatory Strategy, Drug Development, Competitor Analysis, Health Authorities, FDA, EMEA, Marketing Authorization, Clinical Development Plan, Common Technical Document, Orphan Drugs, Paediatric Patients, Submission Strategy, ICH, Pharmacovigilance.
Frequently Asked Questions
What is the primary focus of this research paper?
The paper focuses on "Regulatory Intelligence" and its critical function as a foundation for building a successful regulatory strategy in the pharmaceutical industry, specifically during the drug development process up to the submission of a new drug candidate.
What are the main thematic pillars discussed in the text?
The work revolves around three major components: gathering detailed competitor information, monitoring the global regulatory environment, and adhering to diverse international legal requirements.
What is the ultimate goal of the regulatory strategies proposed?
The goal is to ensure a smooth, efficient transition of drug candidates into marketed products while optimizing the return on investment through "claims-driven" research and development and informed strategic decisions.
Which scientific methods are primarily highlighted?
The paper emphasizes a comprehensive, interdisciplinary approach, utilizing intelligence gathering from regulatory databases, agency benchmarks, scientific literature, and strategic interactions with health authorities.
What does the main body of the work cover regarding strategic planning?
It covers the contributions of regulatory affairs to the global multidisciplinary development plan, including target labelling, trade name selection, clinical development plan design, and the management of regulatory submissions and health authority meetings.
Which keywords best characterize this work?
Key terms include Regulatory Intelligence, Regulatory Strategy, Drug Development, Competitor Analysis, Health Authorities (FDA/EMEA), and Global Submission strategies.
How does the author view the role of Regulatory Affairs?
The author argues against the traditional perception of regulatory affairs as merely a cost-intensive administrative "post office," positioning it instead as an essential, high-value discipline that supports successful drug approvals.
Why is competitor analysis considered essential in this regulatory context?
Competitor analysis is vital because it provides insights into successful development patterns, potential authority hurdles, and market positioning, which helps companies avoid costly mistakes and refine their own development trajectories.
How does the paper address the challenges of EU enlargement and new regulations?
The document stresses the need for continuous monitoring of dynamic regulatory changes (like EU enlargement and the Clinical Trial Directive) to ensure that development dossiers remain compliant at the time of future submission.
- Quote paper
- Petra Heyen (Author), 2004, Regulatory Intelligence as the Basis for Regulatory Strategy and Global Drug Development, Munich, GRIN Verlag, https://www.grin.com/document/38005
